肺腺癌细胞中miR-125a-5p对吉非替尼耐药影响  

Effect of the miR-125a-5p on Grug Resistance in Lung Adenocarcinoma Cells

作　　者：戴璐[1] 傅文凡[1] 陈文彬[1] 

机构地区：[1]广州医科大学附属肿瘤医院肺肿瘤科,510095

出　　处：《中国卫生标准管理》2015年第21期149-150,共2页China Health Standard Management

基　　金：2012年广州医学院青年基金项目(项目编号:2012A14)

摘　　要：目的研究肺腺癌细胞中mi RNA对吉非替尼耐药的影响。方法荧光定量PCR检测mi R-125a-5p在肺腺癌细胞PC9及吉非替尼耐药细胞PC9/GR中的表达;改变mi R-125a-5p在细胞株中的表达,观察其对吉非替尼耐药的影响。结果 mi R-125a-5p在PC9细胞及PC9/GR细胞中表达有差异,增加mi R-125a-5p在PC9中的表达,增加细胞对吉非替尼耐药。结论 mi R-125a-5p可促进肺腺癌细胞对吉非替尼产生耐药。Objective To study the influence of mi RNA to gefitinib resistance in Lung adenocarcinoma cells. Methods The mi R-125a-5p expressions in PC9 and PC9/GR were analyzed by real-time PCR. Observed the influence of the Change of mi R-125a-5p expression to gefitinib resistance. Results The mi R-125a-5p expression in PC9 and PC9/GR were significant differences,and increaseing the mi R-125a-5p expression in PC9 obviously promote drug resistance to gefitinib. Conclusion The mi R-125a-5p can promote drug resistance to gefitinib in Lung adenocarcinoma cells.

关 键 词：肺腺癌 miR-125a-5p 吉非替尼 耐药 

分 类 号：R734.2[医药卫生—肿瘤]